The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02•

All News

Morinaga Milk’s Probiotic Receives Approval of Individual Recognized Registration in South Korea
Biotics and Supplements

Morinaga Milk’s Probiotic Receives Approval of Individual Recognized Registration in South Korea

NOV 28, 2023
Boehringer Ingelheim acquires bacterial cancer therapy specialist T3 Pharma
Finance

Boehringer Ingelheim acquires bacterial cancer therapy specialist T3 Pharma

NOV 22, 2023
Initial patient dosed in Phase 2a clinical trial evaluating first-in-class human milk-based therapy
Clinical & Manufacturing

Initial patient dosed in Phase 2a clinical trial evaluating first-in-class human milk-based therapy

NOV 15, 2023
Synlogic reports Q3 results, including underwritten public offering of $21.0M and $2.5M milestone payment from Roche
Finance

Synlogic reports Q3 results, including underwritten public offering of $21.0M and $2.5M milestone payment from Roche

NOV 11, 2023
Mammalian cells may consume bacteria-killing viruses to promote cellular health
Pharma & Human Health

Mammalian cells may consume bacteria-killing viruses to promote cellular health

NOV 9, 2023
Canada approves gut-brain axis health claims for Chr. Hansen probiotic strain
Biotics and Supplements

Canada approves gut-brain axis health claims for Chr. Hansen probiotic strain

NOV 8, 2023
MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT
Clinical & Manufacturing

MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT

NOV 7, 2023
Seres Therapeutics announces strategic restructuring and third quarter financial results including VOWST™ net sales
Finance

Seres Therapeutics announces strategic restructuring and third quarter financial results including VOWST™ net sales

NOV 6, 2023
Atopic dermatitis: Viruses discovered as new therapy option
Pharma & Human Health

Atopic dermatitis: Viruses discovered as new therapy option

NOV 6, 2023
Engineered bacteria guide CAR-T cells to poorly infiltrated solid tumors
Biotics and Supplements

Engineered bacteria guide CAR-T cells to poorly infiltrated solid tumors

NOV 6, 2023
Using a novel computational approach, researchers confirm microbial diversity is wilder than ever.
Editor's Choice

Using a novel computational approach, researchers confirm microbial diversity is wilder than ever.

OCT 30, 2023